Now CLIA-waived

FebriDx®

Test to treat at the point of care.

> No guessing. No waiting. FebriDx helps your patients get clarity in minutes—so they can get the right care, right away.

PRODUCT OVERVIEW

FebriDx

FebriDx is a rapid, self-contained test that aids in the diagnosis of acute respiratory infection and differentiates bacterial infection from non-bacterial etiology after just 10 minutes—now CLIA-waived for use in near-patient settings.

Using dual biomarkers (**MxA + CRP**), FebriDx detects both viral and bacterial immune responses to guide more accurate, immediate treatment decisions. No instruments, lab equipment, or readers required.

Type	Rapid diagnostic test
Intended use	Differentiate bacterial acute respiratory infections vs. non-bacterial etiology
Sample type	Fingerprick blood sample
Time to result	After 10 minutes
Pack size	25-test kit
Regulatory status	FDA 510(k) cleared
CLIA status	CLIA-waived
Reimbursement code	PLA0442U

Accurate

Dual-biomarker (MxA + CRP) technology with 99% NPV for ruling out bacterial infections[1]

Fast

Results after 10 minutes, supporting on-the-spot treatment decisions

Instrument-free

No reader, equipment, or lab processing required (fully self-contained)

CLIA-waived

For use in a wide range of point-of-care settings, extending diagnostic capability beyond the lab

How to use

Now even easier to implement—waived for use in any CLIA-certified waived facility.

1. Collect a fingerstick blood sample (lancet included in device)
2. Transfer the blood to the test strip via capillary action
3. Push the buffer release button
4. Read results after 10 minutes

Result interpretation



Refer to the complete IFU on our FebriDx webpage.
phasescientificamericas.com/products-and-services/indicaid-poc/indicaid-febridx-test

POINT-OF-CARE INSIGHTS

Antibiotic clarity. POC-ready. CLIA-waived.

- **Elevate your clinical role**
  Support timely, informed decisions across point-of-care settings
- **Help guide smarter decisions**
  FebriDx clarifies if symptoms are likely due to bacterial infection, supporting responsible antibiotic use
- **Fast, actionable, and accessible**
  Test and interpret results during a single visit. No instruments or lab equipment required
- **Improve practice workflow with rapid test results**
  Ensure that bacterial infections are not overlooked

Clinical power
Assess and act in one visit

Trusted results
Dual biomarkers guide treatment

Waived & ready
CLIA-waived and fully instrument-free

Ideal use case

FebriDx is now cleared and CLIA-waived for point-of-care testing in urgent care, primary care, retail clinics and employer health programs. Use with patients presenting with:

- Cold and flu-like symptoms
- Fever, sore throat, or cough
- Nasal congestion
- Shortness of breath
- Symptoms <7 days and within 3 days of fever onset

Why FebriDx fits here

Expands access: Now eligible for use in CLIA-waived facilities—no lab license required

Empowers frontline care: Enables same-visit diagnosis and antibiotic stewardship in Urgent Care, Primary Care, Pharmacy Clinics and Occupational Settings

Reduces unnecessary prescriptions: Clarifies whether an infection is likely bacterial or non-bacterial during a test visit

Supports public health: Decreases antibiotic misuse and improves patient satisfaction

Contact us today to place an order: 657-233-5880 | USsales@phasesci.com

FebriDx® is FDA 510(k) cleared for prescription use only. It is intended for use in patients aged 12 to 64 presenting with signs and symptoms of acute respiratory infection, who have had symptoms for less than 7 days and within three days of fever onset. FebriDx results are to be used in conjunction with other clinical and diagnostic findings and are not intended as a stand-alone diagnostic tool. This test does not identify specific pathogens or determine infection severity. FebriDx is intended for use by healthcare professionals in CLIA-waived settings.

Shapiro NI, Filbin MR, Hou PC, et al. Diagnostic accuracy of a bacterial and viral biomarker point-of-care test in the outpatient setting. JAMA Netw Open, 2022, 5(10): e2234588.
U.S. Food and Drug Administration. 510(k) summary for FebriDx Bacterial/Non-Bacterial Point-of-Care Assay. K260787.

Distributed in partnership with Lumos Diagnostics.

MKT-MC-0136 V 1.1